ezrin和nm-23在乳腺癌中的表达及其临床意义

目的：研究乳腺癌组织中ezrin和nm-23蛋白表达与乳腺癌临床因素和预后的关系。方法：应用免疫组化S—P方法，检测63例乳腺癌癌组织，20例癌旁组织，及30例乳腺良性肿瘤中的ezrin和nm-23表达。结果：ezrin和nm-23在乳腺良性肿瘤和乳腺癌癌旁组织中均无异常表达。在乳腺癌组织中ezrin和nm-23的表达率分别为55．56％（35／63）和52．38％（33／63），ezrin在乳腺癌中的表达和淋巴结转移，临床分期呈正相关而和无病生存时间呈负相关（P〈0．05），nm-23的表达和淋巴结转移，临床分期呈负相关而和无病生存时间呈正相关（P〈0．05），ezrin和nm～23在乳腺癌中的表达和年龄、肿块大小以及月经情况无相关性（P〉0．05）。结论：检测ezrin和nm-23在乳腺癌中的表达有助于判断乳腺癌的转移潜能和预后。

Expression of ezrin and nm- 23 proteins in breast cancer and their clinical significance

Objective：To explore the expression and clinical significance of ezrin and nm -23 in breast cancer, and to evaluate the relationship with prognosis. Methods： Immunohistochemical staining（ s -p） was used to detect the expression of ezrin and nm - 23 in 63 cases of breast cancer,20 cases of corresponding adjacent tissues and 30 cases of benign tumor. Results： No abnormal expression of ezrin and nm - 23 in benign tumors and corresponding adjacent tissues was observed. In 63 cases of breast cancer , the abnomal expression rates of ezrin and nm - 23 were 55.56% and 52.38% （33/63） , respectively. The expression of ezrin positively correlated with lymph node metastasis and clinical stage , while negatively correlated with DFS（P 〈0. 05）,nm-23 negatively correlated with lymph node me- tastasis, clinical stage and positively correlate with DFS（P 〈0. 05） ,but had no statistical relationship with tumor size,age and menopausal status （P 〉0. 05）. Conclusion：Measurement of ezrin and nm -23 expression may have prognostic value for assessing the degree of malignancy and potential lymph node metastasis probability of breast cancer.